Wei Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei Peng has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Carrie Daniel-MacDougall
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
7 shared publications - Joseph F. Petrosino
The Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
7 shared publications - Kristi Hoffman
Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, Houston, Texas
7 shared publications Diao Kong
Division of Hepatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China
6 shared publicationsKplola Y. Elhor Gbito
6 shared publications- Paul Scheet
Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
6 shared publications
Latest Publications
- 10 June 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (6) , e70497
Eating Difficulties, Psychological Distress, and Self‐Management in Colorectal Cancer Patients Undergoing Chemotherapy: A Qualitative Study
Objective: To explore eating difficulties, psychological distress and self‐management strategies among colorectal cancer (CRC) patients receiving chemotherapy, and to examine how diet‐related symptom burden shapes emotional responses, perceived control and coping, guided by Symptom Management Theory (SMT). Methods: A qualitative study was conducted with 22 CRC patients receiving chemotherapy at two tertiary hospitals in Chengdu. Purposive sampling ensured variation in demographic and clinical characteristics. Semi‐structured interviews were audio‐recorded, transcribed verbatim, and analyzed using reflexive thematic analysis informed by SMT. The study was reported in line with the Consolidated criteria for reporting qualitative research (COREQ). Results: Three main themes were identified: (1) Diet‐related symptom distress and disrupted eating: patients described complex, fluctuating multisystem symptom clusters that reduced appetite, altered taste, and eroded a sense of control over eating. (2) Dietary self‐management as coping and regaining control: patients engaged in flexible dietary adjustments, trial‐and‐error experimentation, timing and portion modifications, and emotional regulation to alleviate discomfort, preserve daily functioning, and maintain social roles. (3) Uncertainty and unmet psychosocial‐nutritional support needs: patients reported confusion about “right” foods and quantities, fear that diet might compromise treatment, exposure to conflicting information, and a desire for structured, accessible, and personalised guidance that addresses both nutritional and emotional concerns. Conclusions: Eating during chemotherapy is both psychosocial and nutritional, intertwining symptom burden, emotional responses, perceived control, and coping efforts. Integrating patient‐centered nutritional care with psycho‐oncological support, through multidisciplinary collaboration, may improve symptom control, treatment adherence, and quality of life in CRC patients.
- 10 June 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (6) , e70497
Eating Difficulties, Psychological Distress, and Self‐Management in Colorectal Cancer Patients Undergoing Chemotherapy: A Qualitative Study
Objective: To explore eating difficulties, psychological distress and self‐management strategies among colorectal cancer (CRC) patients receiving chemotherapy, and to examine how diet‐related symptom burden shapes emotional responses, perceived control and coping, guided by Symptom Management Theory (SMT). Methods: A qualitative study was conducted with 22 CRC patients receiving chemotherapy at two tertiary hospitals in Chengdu. Purposive sampling ensured variation in demographic and clinical characteristics. Semi‐structured interviews were audio‐recorded, transcribed verbatim, and analyzed using reflexive thematic analysis informed by SMT. The study was reported in line with the Consolidated criteria for reporting qualitative research (COREQ). Results: Three main themes were identified: (1) Diet‐related symptom distress and disrupted eating: patients described complex, fluctuating multisystem symptom clusters that reduced appetite, altered taste, and eroded a sense of control over eating. (2) Dietary self‐management as coping and regaining control: patients engaged in flexible dietary adjustments, trial‐and‐error experimentation, timing and portion modifications, and emotional regulation to alleviate discomfort, preserve daily functioning, and maintain social roles. (3) Uncertainty and unmet psychosocial‐nutritional support needs: patients reported confusion about “right” foods and quantities, fear that diet might compromise treatment, exposure to conflicting information, and a desire for structured, accessible, and personalised guidance that addresses both nutritional and emotional concerns. Conclusions: Eating during chemotherapy is both psychosocial and nutritional, intertwining symptom burden, emotional responses, perceived control, and coping efforts. Integrating patient‐centered nutritional care with psycho‐oncological support, through multidisciplinary collaboration, may improve symptom control, treatment adherence, and quality of life in CRC patients.
- Open Access
- 9 June 2026
- Published by Springer Nature in Journal of Nanobiotechnology
In vivo generation of fibrolytic macrophages via LNP-CSF1 mRNA attenuates liver fibrosis
Liver fibrosis, a common consequence of chronic liver injury, imposes a substantial global health burden. While autologous infusion of ex vivo-induced macrophages has shown therapeutic potential, such cell-based strategies remain limited by high costs and operational complexity, underscoring the necessity for non-cellular alternatives. Here, we aim to directly generate therapeutic macrophages with fibrolytic capacity within the liver. We observed elevated levels of macrophage colony-stimulating factor 1 (CSF1) during the resolution of liver regeneration-induced fibrosis. Given the well-established role of CSF1 in recruiting and activating monocyte-macrophages, as well as its use as a key cytokine for the ex vivo induction of therapeutic macrophages, we delivered CSF1-mRNA via lipid nanoparticles (LNPs) to enhance its local expression in the liver. This approach effectively recruited macrophages and promoted their differentiation into a fibrolytic phenotype. The in vivo-generated macrophages exhibited increased collagenase expression and enhanced phagocytic activity. Moreover, their transcriptomic and functional profiles closely resembled those of ex vivo-induced therapeutic macrophages. This approach significantly alleviated fibrosis in multiple mouse models. Together, this work provides preclinical proof of concept that LNP-CSF1-based in situ cellular therapy represents a promising non-cellular strategy for combating liver fibrosis.
- 9 June 2026
- Published by Springer Nature in Journal of Nanobiotechnology
Open AccessIn vivo generation of fibrolytic macrophages via LNP-CSF1 mRNA attenuates liver fibrosis
Liver fibrosis, a common consequence of chronic liver injury, imposes a substantial global health burden. While autologous infusion of ex vivo-induced macrophages has shown therapeutic potential, such cell-based strategies remain limited by high costs and operational complexity, underscoring the necessity for non-cellular alternatives. Here, we aim to directly generate therapeutic macrophages with fibrolytic capacity within the liver. We observed elevated levels of macrophage colony-stimulating factor 1 (CSF1) during the resolution of liver regeneration-induced fibrosis. Given the well-established role of CSF1 in recruiting and activating monocyte-macrophages, as well as its use as a key cytokine for the ex vivo induction of therapeutic macrophages, we delivered CSF1-mRNA via lipid nanoparticles (LNPs) to enhance its local expression in the liver. This approach effectively recruited macrophages and promoted their differentiation into a fibrolytic phenotype. The in vivo-generated macrophages exhibited increased collagenase expression and enhanced phagocytic activity. Moreover, their transcriptomic and functional profiles closely resembled those of ex vivo-induced therapeutic macrophages. This approach significantly alleviated fibrosis in multiple mouse models. Together, this work provides preclinical proof of concept that LNP-CSF1-based in situ cellular therapy represents a promising non-cellular strategy for combating liver fibrosis.
- Open Access
- 1 June 2026
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 15 (3) , 66
Impact of metabolic dysfunction-associated steatotic liver disease on long-term prognosis in hepatocellular carcinoma patients undergoing hepatectomy
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has been recognized as an accurate reflection of the pathogenesis of fatty liver disease by a consensus document. However, the relationship between MASLD and the prognosis of hepatocellular carcinoma (HCC) patients receiving hepatectomy remains unclear. The aim of this study is to investigate whether MASLD affects the long-term prognosis of HCC patients undergoing hepatectomy. Methods: A multivariate Cox proportional hazards model and a propensity score matching (PSM) analysis were implemented to ensure equal baseline characteristics. The Kaplan-Meier survival curves were employed for prognosis comparison between the two groups. Results: This study involved 909 HCC patients who underwent hepatectomy between January 2011 and December 2017 at the West China Hospital of Sichuan University, including 97 patients with MASLD (MASLD group) and 812 patients without MASLD (non-MASLD group). According to the multivariate analysis, patients in the MASLD group showed worse recurrence-free survival (RFS) [hazard ratio (HR) =1.23; 95% confidence interval (CI), 1.13–1.72; P=0.03] and overall survival (OS) (HR =2.04; 95% CI, 1.06–2.73; P=0.03) than those in the non-MASLD group. After conducting a PSM analysis, Kaplan-Meier survival curve analysis disclosed significant differences in both the RFS and OS between the two groups (P=0.02 and P=0.01, respectively). All results showed that MASLD had a poor long-term prognosis for HCC patients undergoing hepatectomy. Conclusions: In summary, our study suggests that MASLD might be a risk factor for the OS and RFS in HCC patients who underwent hepatectomy through multivariate analysis and PSM analysis. These findings indicate that preoperative diagnosis of MASLD in HCC patients holds crucial significance in guiding the long-term prognosis of patients after hepatectomy.
- 1 June 2026
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 15 (3) , 66
Open AccessImpact of metabolic dysfunction-associated steatotic liver disease on long-term prognosis in hepatocellular carcinoma patients undergoing hepatectomy
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has been recognized as an accurate reflection of the pathogenesis of fatty liver disease by a consensus document. However, the relationship between MASLD and the prognosis of hepatocellular carcinoma (HCC) patients receiving hepatectomy remains unclear. The aim of this study is to investigate whether MASLD affects the long-term prognosis of HCC patients undergoing hepatectomy. Methods: A multivariate Cox proportional hazards model and a propensity score matching (PSM) analysis were implemented to ensure equal baseline characteristics. The Kaplan-Meier survival curves were employed for prognosis comparison between the two groups. Results: This study involved 909 HCC patients who underwent hepatectomy between January 2011 and December 2017 at the West China Hospital of Sichuan University, including 97 patients with MASLD (MASLD group) and 812 patients without MASLD (non-MASLD group). According to the multivariate analysis, patients in the MASLD group showed worse recurrence-free survival (RFS) [hazard ratio (HR) =1.23; 95% confidence interval (CI), 1.13–1.72; P=0.03] and overall survival (OS) (HR =2.04; 95% CI, 1.06–2.73; P=0.03) than those in the non-MASLD group. After conducting a PSM analysis, Kaplan-Meier survival curve analysis disclosed significant differences in both the RFS and OS between the two groups (P=0.02 and P=0.01, respectively). All results showed that MASLD had a poor long-term prognosis for HCC patients undergoing hepatectomy. Conclusions: In summary, our study suggests that MASLD might be a risk factor for the OS and RFS in HCC patients who underwent hepatectomy through multivariate analysis and PSM analysis. These findings indicate that preoperative diagnosis of MASLD in HCC patients holds crucial significance in guiding the long-term prognosis of patients after hepatectomy.
- Open Access
- 28 March 2026
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 17
Association of insulin resistance-related indicators with cardiovascular disease and cardiovascular disease mortality in individuals with MASLD: a population-based study
Background: Limited studies have explored the relationship between surrogate markers of insulin resistance (IR) with both cardiovascular disease (CVD) risk and CVD mortality in individuals with metabolic dysfunction-associated fatty liver disease (MASLD). This study aimed to assess the associations of various IR surrogates with CVD risk and mortality and to identify effective predictors of cardiovascular outcomes in this population. Design: This study constituted a population-based cross-sectional investigation, utilizing data derived from six cycles of the National Health and Nutrition Examination Survey (NHANES) spanning from 2005 to 2016. The data were linked to the NHANES public-use linked mortality files up to December 31, 2019, to facilitate follow-up on CVD mortality. Following predefined exclusion criteria, participants diagnosed with MASLD were identified and incorporated into the study. The research assessed the associations between surrogate markers of IR and both the prevalence of CVD and CVD mortality. Methods: The primary outcome of this study was the incidence of CVD in individuals with MASLD, and the secondary outcome was CVD mortality. Weighted multivariate logistic regression was utilized to examine the relationship between surrogate markers of IR with total CVD and other subtypes. Weighted multivariate Cox regression and Kaplan–Meier analysis were used to examine the relationship between surrogate markers of IR and CVD mortality. Restricted cubic spline (RCS) was used to explore potential nonlinear relationships. Receiver operating characteristics (ROC) and calibration curves were plotted to evaluate the discriminability and accuracy of IR surrogate markers in predicting CVD risk. Furthermore, mediation analysis was conducted to determine whether surrogate markers of liver fibrosis play a mediating role in the association of surrogate markers of IR with the risk of total CVD and other subtypes. Results: This study suggests that in the fully adjusted model, estimated glucose disposal rate (eGDR) was significantly negatively correlated with total CVD, congestive heart failure (CHF), heart attack (HA), and CVD mortality. Metabolic score for IR and triglyceride-glucose-body mass index were significantly positively correlated with CVD mortality, total CVD, and CHF. eGDR was best correlated with total CVD (odds ratio (OR) = 0.40, 95% confidence interval (CI): 0.25, 0.63), CHF (OR = 0.15, 95% CI: 0.06, 0.38), and HA (OR = 0.40, 95% CI: 0.22, 0.71). Weighted multivariate Cox regression indicated that for each unit increase in eGDR, the risk of CVD mortality decreased by 27%. RCS analysis showed that all surrogate markers of IR were linearly related to CVD and CVD mortality ( P -nonlinear relationship >0.05). In addition, the ROC curve showed that eGDR had a more robust diagnostic efficacy than other IR markers, and eGDR had a higher accuracy in predicting long-term CVD mortality. Adding eGDR to the base model improved the C statistic, net reclassification improvement, and composite discrimination improvement for most outcome variables. In mediation analysis, Metabolic Dysfunction Associated Fibrosis 5 mediated part of the association between eGDR and total CVD, coronary heart disease, HA, and stroke. Conclusion: In conclusion, eGDR outperformed other IR surrogates in predicting both CVD risk and CVD mortality in MASLD. Incorporating eGDR into prediction models may enhance risk stratification and facilitate early identification of high-risk individuals in this population. Further studies are warranted to validate these findings in external cohorts.
- 28 March 2026
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 17
Open AccessAssociation of insulin resistance-related indicators with cardiovascular disease and cardiovascular disease mortality in individuals with MASLD: a population-based study
Background: Limited studies have explored the relationship between surrogate markers of insulin resistance (IR) with both cardiovascular disease (CVD) risk and CVD mortality in individuals with metabolic dysfunction-associated fatty liver disease (MASLD). This study aimed to assess the associations of various IR surrogates with CVD risk and mortality and to identify effective predictors of cardiovascular outcomes in this population. Design: This study constituted a population-based cross-sectional investigation, utilizing data derived from six cycles of the National Health and Nutrition Examination Survey (NHANES) spanning from 2005 to 2016. The data were linked to the NHANES public-use linked mortality files up to December 31, 2019, to facilitate follow-up on CVD mortality. Following predefined exclusion criteria, participants diagnosed with MASLD were identified and incorporated into the study. The research assessed the associations between surrogate markers of IR and both the prevalence of CVD and CVD mortality. Methods: The primary outcome of this study was the incidence of CVD in individuals with MASLD, and the secondary outcome was CVD mortality. Weighted multivariate logistic regression was utilized to examine the relationship between surrogate markers of IR with total CVD and other subtypes. Weighted multivariate Cox regression and Kaplan–Meier analysis were used to examine the relationship between surrogate markers of IR and CVD mortality. Restricted cubic spline (RCS) was used to explore potential nonlinear relationships. Receiver operating characteristics (ROC) and calibration curves were plotted to evaluate the discriminability and accuracy of IR surrogate markers in predicting CVD risk. Furthermore, mediation analysis was conducted to determine whether surrogate markers of liver fibrosis play a mediating role in the association of surrogate markers of IR with the risk of total CVD and other subtypes. Results: This study suggests that in the fully adjusted model, estimated glucose disposal rate (eGDR) was significantly negatively correlated with total CVD, congestive heart failure (CHF), heart attack (HA), and CVD mortality. Metabolic score for IR and triglyceride-glucose-body mass index were significantly positively correlated with CVD mortality, total CVD, and CHF. eGDR was best correlated with total CVD (odds ratio (OR) = 0.40, 95% confidence interval (CI): 0.25, 0.63), CHF (OR = 0.15, 95% CI: 0.06, 0.38), and HA (OR = 0.40, 95% CI: 0.22, 0.71). Weighted multivariate Cox regression indicated that for each unit increase in eGDR, the risk of CVD mortality decreased by 27%. RCS analysis showed that all surrogate markers of IR were linearly related to CVD and CVD mortality ( P -nonlinear relationship >0.05). In addition, the ROC curve showed that eGDR had a more robust diagnostic efficacy than other IR markers, and eGDR had a higher accuracy in predicting long-term CVD mortality. Adding eGDR to the base model improved the C statistic, net reclassification improvement, and composite discrimination improvement for most outcome variables. In mediation analysis, Metabolic Dysfunction Associated Fibrosis 5 mediated part of the association between eGDR and total CVD, coronary heart disease, HA, and stroke. Conclusion: In conclusion, eGDR outperformed other IR surrogates in predicting both CVD risk and CVD mortality in MASLD. Incorporating eGDR into prediction models may enhance risk stratification and facilitate early identification of high-risk individuals in this population. Further studies are warranted to validate these findings in external cohorts.
- 21 October 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (28) , 3611-3617
PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma
The unsatisfactory prognosis of patients with early-stage hepatocellular carcinoma (HCC) emphasizes the urgent need for perioperative treatment to reduce recurrence after surgery. The combination of transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and programmed cell death protein 1 (PD-1) inhibitor has emerged as a promising treatment for unresectable HCC, yet its perioperative application was not explored. PERI-START is a prospective, single arm phase II trial which aims to investigate the efficacy and safety of TACE, tislelizumab (PD-1 inhibitor), and lenvatinib (TKI) in perioperative (neoadjuvant and adjuvant) use for resectable, high-risk HCC. Within 1 week after enrollment, TACE will be administered. Subsequently, intravenous tislelizumab will be given every 3 weeks in combination with daily oral lenvatinib. Unless disease progression occurs, liver resection will then be performed. 4-6 weeks after liver resection, tislelizumab and lenvatinib will be resumed for 6 months. The primary endpoint is the major pathological response (MPR) rate, with secondary endpoints including objective response rate (ORR), R0 resection rate, event-free survival (EFS), overall survival (OS), and adverse events (AEs).Clinical trial registration: ChiCTR2400085067 (www.chictr.org.cn).
- 21 October 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (28) , 3611-3617
PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma
The unsatisfactory prognosis of patients with early-stage hepatocellular carcinoma (HCC) emphasizes the urgent need for perioperative treatment to reduce recurrence after surgery. The combination of transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and programmed cell death protein 1 (PD-1) inhibitor has emerged as a promising treatment for unresectable HCC, yet its perioperative application was not explored. PERI-START is a prospective, single arm phase II trial which aims to investigate the efficacy and safety of TACE, tislelizumab (PD-1 inhibitor), and lenvatinib (TKI) in perioperative (neoadjuvant and adjuvant) use for resectable, high-risk HCC. Within 1 week after enrollment, TACE will be administered. Subsequently, intravenous tislelizumab will be given every 3 weeks in combination with daily oral lenvatinib. Unless disease progression occurs, liver resection will then be performed. 4-6 weeks after liver resection, tislelizumab and lenvatinib will be resumed for 6 months. The primary endpoint is the major pathological response (MPR) rate, with secondary endpoints including objective response rate (ORR), R0 resection rate, event-free survival (EFS), overall survival (OS), and adverse events (AEs).Clinical trial registration: ChiCTR2400085067 (www.chictr.org.cn).
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 1031-1041
Transarterial Chemoembolization, Molecular Targeted Treatments, and Programmed Death-(Ligand)1 Inhibitors, for Hepatocellular Carcinoma with Lung Metastasis: A Retrospective Cohort Study
Background: Treatment options for patients with hepatocellular carcinoma (HCC) and lung metastases are diverse, requiring a personalized approach. Current CNLC guidelines recommend systemic therapy and focal radiation, emphasizing the roles of molecular targeted treatments (MTT) and programmed death-(ligand)1 (PD-[L]1) inhibitors. However, the efficacy of combining TACE with these treatments remains uncertain. Purpose: To compare the efficacy and adverse reactions of TACE combined with MTT and PD-(L)1 versus MTT and (PD-[L]1) in patients with HCC and lung metastasis. Materials and Methods: We retrospectively analyzed data from patients treated between January 2019 and May 2024 at the Affiliated Hospital of Southwest Medical University and West China Hospital of Sichuan University. Stabilized inverse probability weighting was employed to reduce bias. The primary outcome was overall survival (OS); secondary outcomes included progression-free survival (PFS) and objective response rate (ORR). Results: Among 167 patients, 141 received TACE, MTT, and PD-(L)1, while 26 received MTT and PD-(L)1. The median follow-up times were 28 and 29 months, respectively. After weighting, baseline characteristics were well balanced. The median OS was significantly longer in the TACE group (15 months) compared to the MTT group (8 months; p=0.023), and PFS was also longer (8 months vs 5 months; p=0.038). For liver lesions, ORR was 42.6% in the TACE group and 46.2% in the MTT group (p=0.73); for lung lesions, ORR was 26.2% and 19.2%, respectively (p=0.449). Safety profiles were similar, except for a higher incidence of rash in the MTT group. Conclusion: TACE combined with MTT and PD-(L)1 demonstrated better outcomes for patients with liver cancer and lung metastases compared to MTT and PD-(L)1 alone, without increasing complication rates, suggesting a promising first-line treatment option.
- 1 May 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 1031-1041
Open AccessTransarterial Chemoembolization, Molecular Targeted Treatments, and Programmed Death-(Ligand)1 Inhibitors, for Hepatocellular Carcinoma with Lung Metastasis: A Retrospective Cohort Study
Background: Treatment options for patients with hepatocellular carcinoma (HCC) and lung metastases are diverse, requiring a personalized approach. Current CNLC guidelines recommend systemic therapy and focal radiation, emphasizing the roles of molecular targeted treatments (MTT) and programmed death-(ligand)1 (PD-[L]1) inhibitors. However, the efficacy of combining TACE with these treatments remains uncertain. Purpose: To compare the efficacy and adverse reactions of TACE combined with MTT and PD-(L)1 versus MTT and (PD-[L]1) in patients with HCC and lung metastasis. Materials and Methods: We retrospectively analyzed data from patients treated between January 2019 and May 2024 at the Affiliated Hospital of Southwest Medical University and West China Hospital of Sichuan University. Stabilized inverse probability weighting was employed to reduce bias. The primary outcome was overall survival (OS); secondary outcomes included progression-free survival (PFS) and objective response rate (ORR). Results: Among 167 patients, 141 received TACE, MTT, and PD-(L)1, while 26 received MTT and PD-(L)1. The median follow-up times were 28 and 29 months, respectively. After weighting, baseline characteristics were well balanced. The median OS was significantly longer in the TACE group (15 months) compared to the MTT group (8 months; p=0.023), and PFS was also longer (8 months vs 5 months; p=0.038). For liver lesions, ORR was 42.6% in the TACE group and 46.2% in the MTT group (p=0.73); for lung lesions, ORR was 26.2% and 19.2%, respectively (p=0.449). Safety profiles were similar, except for a higher incidence of rash in the MTT group. Conclusion: TACE combined with MTT and PD-(L)1 demonstrated better outcomes for patients with liver cancer and lung metastases compared to MTT and PD-(L)1 alone, without increasing complication rates, suggesting a promising first-line treatment option.
- Open Access
- 1 April 2025
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 14 (2) , 301-304
Efficacy and challenges of combining transarterial chemoembolization with pembrolizumab in advanced hepatocellular carcinoma: insights from the PETAL study
Efficacy and challenges of combining transarterial chemoembolization with pembrolizumab in advanced hepatocellular carcinoma: insights from the PETAL study
- 1 April 2025
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 14 (2) , 301-304
Open AccessEfficacy and challenges of combining transarterial chemoembolization with pembrolizumab in advanced hepatocellular carcinoma: insights from the PETAL study
Efficacy and challenges of combining transarterial chemoembolization with pembrolizumab in advanced hepatocellular carcinoma: insights from the PETAL study
- 11 March 2025
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (5) , 102011
Curative resection of Castleman disease initially misdiagnosed as gastrointestinal stromal tumor
- 11 March 2025
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (5) , 102011
Curative resection of Castleman disease initially misdiagnosed as gastrointestinal stromal tumor
- 9 October 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (12) , 2140-2142
Giant hepatic angiomyolipoma mimicking hepatocellular carcinoma
- 9 October 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (12) , 2140-2142
Giant hepatic angiomyolipoma mimicking hepatocellular carcinoma
- Open Access
- 19 July 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-9
Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial
Background: The high recurrence rate after liver resection emphasizes the urgent need for neoadjuvant therapy in hepatocellular carcinoma (HCC) to enhance the overall prognosis for patients. Immune checkpoint inhibitors, camrelizumab combined with an anti-angiogenic tyrosine kinase inhibitor (TKI) apatinib, have emerged as a first-line treatment option for patients with unresectable HCC, yet its neoadjuvant application in combination with transarterial chemoembolization (TACE) in HCC remains unexplored. Therefore, this study aims to investigate the efficacy and safety of sequential TACE, camrelizumab, and apatinib as a neoadjuvant therapy for single, huge HCC. Methods: This multi-center, open-label randomized phase 3 trial will be conducted at 7 tertiary hospitals. Patients with single huge (≥ 10 cm in diameter), resectable HCC will be randomly assigned in a 1:1 ratio to arm of surgery alone or arm of neoadjuvant therapy followed by surgery. In the neoadjuvant therapy group, patients will receive TACE within 1 week after randomization, followed by camrelizumab (200 mg q2w, 4 cycles), along with apatinib (250 mg qd, 2 months). Patients will receive liver resection after neoadjuvant therapy unless the disease is assessed as progressive. The primary outcome is recurrence-free survival (RFS) at 1 year. The planned sample size of 60 patients will be calculated to permit the accumulation of sufficient RFS events in 1 year to achieve 80% power for the RFS primary endpoint. Discussion: Synergistic effects provided by multimodality therapy of locoregional treatment, TKI, and anti-programmed cell death 1 inhibitor significantly improved overall survival for patients with unresectable HCC. Our trial will investigate the efficacy and safety of the triple combination of TACE, camrelizumab, and apatinib as a neoadjuvant strategy for huge, resectable HCC. Trial registration: www.chitr.org.cn ChiCTR2300078086. Registered on November 28, 2023. Start recruitment: 1st January 2024. Expected completion of recruitment: 15th June 2025.
- 19 July 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-9
Open AccessNeoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial
Background: The high recurrence rate after liver resection emphasizes the urgent need for neoadjuvant therapy in hepatocellular carcinoma (HCC) to enhance the overall prognosis for patients. Immune checkpoint inhibitors, camrelizumab combined with an anti-angiogenic tyrosine kinase inhibitor (TKI) apatinib, have emerged as a first-line treatment option for patients with unresectable HCC, yet its neoadjuvant application in combination with transarterial chemoembolization (TACE) in HCC remains unexplored. Therefore, this study aims to investigate the efficacy and safety of sequential TACE, camrelizumab, and apatinib as a neoadjuvant therapy for single, huge HCC. Methods: This multi-center, open-label randomized phase 3 trial will be conducted at 7 tertiary hospitals. Patients with single huge (≥ 10 cm in diameter), resectable HCC will be randomly assigned in a 1:1 ratio to arm of surgery alone or arm of neoadjuvant therapy followed by surgery. In the neoadjuvant therapy group, patients will receive TACE within 1 week after randomization, followed by camrelizumab (200 mg q2w, 4 cycles), along with apatinib (250 mg qd, 2 months). Patients will receive liver resection after neoadjuvant therapy unless the disease is assessed as progressive. The primary outcome is recurrence-free survival (RFS) at 1 year. The planned sample size of 60 patients will be calculated to permit the accumulation of sufficient RFS events in 1 year to achieve 80% power for the RFS primary endpoint. Discussion: Synergistic effects provided by multimodality therapy of locoregional treatment, TKI, and anti-programmed cell death 1 inhibitor significantly improved overall survival for patients with unresectable HCC. Our trial will investigate the efficacy and safety of the triple combination of TACE, camrelizumab, and apatinib as a neoadjuvant strategy for huge, resectable HCC. Trial registration: www.chitr.org.cn ChiCTR2300078086. Registered on November 28, 2023. Start recruitment: 1st January 2024. Expected completion of recruitment: 15th June 2025.